跳至主要内容
临床试验/EUCTR2005-000963-25-Outside-EU/EEA
EUCTR2005-000963-25-Outside-EU/EEA进行中(未招募)不适用

A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil in the Treatment of Subjects Who Have Completed Study A1481131 - N/A

Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK0 个研究点目标入组 220 人开始时间: 2012年3月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
220

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • · Pediatric subjects, who enrolled in and completed Study A1481131;
  • · Females of childbearing potential who are sexually active must be practicing a suitable method of birth control so that in the opinion of the investigator, they will not become pregnant during the study; and
  • · The investigator must obtain written informed consent and assent where applicable before the subject is considered for enrollment in Study A1481156. The inclusion of a subject more than once in the same clinical trial is not permissible.
  • All inclusion criteria must be adhered to.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 217
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 3
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pediatric subjects, who did not complete Study A1481131.
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis
  • pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
  • The exclusion criteria must be adhered to.

研究者

发起方
Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK

相似试验